Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice. / Brynskov, Troels ; Kemp, Henrik; Sørensen, Torben Lykke.
In: Retina, Vol. 34, No. 8, 08.2014, p. 1637–1643.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Brynskov, T, Kemp, H & Sørensen, TL 2014, 'Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice.', Retina, vol. 34, no. 8, pp. 1637–1643. https://doi.org/10.1097/IAE.0000000000000111
APA
Brynskov, T., Kemp, H., & Sørensen, T. L. (2014). Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice. Retina, 34(8), 1637–1643. https://doi.org/10.1097/IAE.0000000000000111
Vancouver
Brynskov T, Kemp H, Sørensen TL. Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice. Retina. 2014 Aug;34(8):1637–1643. https://doi.org/10.1097/IAE.0000000000000111
Author
Bibtex
@article{3b201e748cf64b3ca0dc856b9a9b0c55,
title = "Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice.",
author = "Troels Brynskov and Henrik Kemp and S{\o}rensen, {Torben Lykke}",
year = "2014",
month = aug,
doi = "10.1097/IAE.0000000000000111",
language = "English",
volume = "34",
pages = "1637–1643",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams & Wilkins",
number = "8",
}
RIS
TY - JOUR
T1 - Intravitreal ranibizumab for retinal vein occlusion through 1 year use in clinical practice.
AU - Brynskov, Troels
AU - Kemp, Henrik
AU - Sørensen, Torben Lykke
PY - 2014/8
Y1 - 2014/8
U2 - 10.1097/IAE.0000000000000111
DO - 10.1097/IAE.0000000000000111
M3 - Journal article
C2 - 24646663
VL - 34
SP - 1637
EP - 1643
JO - Retina
JF - Retina
SN - 0275-004X
IS - 8
ER -
ID: 96080570